With Success From Big And Small Pharma Alliances, Contract Sales Firm Invida Hunts For Big Brand Buyouts In India
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Large marketing opportunities in Asian countries like India, China, Malaysia and Philippines are being best tapped by big companies having ample financial resources, well-oiled infrastructure and an established marketing network. But for the scores of smaller specialty pharma or biotechnology units, which boast of a few brands but have no inclination to build a cost-heavy marketing structure, contract sales organization Invida is positioning itself as the right gateway to spread out into the world's fastest-growing South Asian pharmaceutical marketplaces
You may also be interested in...
Invida Charts 25% Growth Plan, Banking On Selective Partnerships For High-value Products
SINGAPORE - Big Pharma's slow shift from primary care products to specialty care products like the oncology segment has helped Invida develop robust commercial relationships with multiple partners
Invida Charts 25% Growth Plan, Banking On Selective Partnerships For High-value Products
SINGAPORE - Big Pharma's slow shift from primary care products to specialty care products like the oncology segment has helped Invida develop robust commercial relationships with multiple partners
Invida Goes Deeper In Skincare, Teams With Sinclair To Expand In Asia Pacific
UK specialty drug maker Sinclair signed a collaborative deal Dec. 7 with Singapore-based Invida to commercialize a number of dermatology products in 11 Asian markets. While multinational drug makers are accelerating expansion in Asia, specialty pharmaceutical companies are teaming up with contract sales firms such as Invida to capitalize on increasing demand in the region